Navigation Links
Novel protein may help detect Lou Gehrig's disease and dementia, Mayo Clinic finds
Date:2/12/2013

JACKSONVILLE, Fla. Researchers at Mayo Clinic have discovered an abnormal protein that accumulates in the brains of many patients affected with two common neurodegenerative disorders amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease, and frontotemporal dementia. They say their findings have uncovered a potentially new therapeutic target and biomarker that would allow clinicians to confirm diagnosis of the diseases. The study is published online today in the journal Neuron.

The Mayo research team, led by scientists at Mayo Clinic's campus in Florida, discovered the abnormal protein pathology that they call C9RANT. An error in the highly regulated cellular process through which proteins are generated causes the abnormal production of C9RANT. The team developed an antibody that can detect the specific, insoluble protein that clumps together and is present in patients with mutations in the C9ORF72 gene, which was previously identified by Mayo Clinic researchers as the most common genetic cause of ALS and frontotemporal dementia.

"This new finding sheds light on how the mutation causes these disorders, and it provides us with a marker that helps us track disease progression in patients with this disorder and potentially combat the disease," says senior author Leonard Petrucelli, Ph.D., a molecular neuroscientist and director of the Department of Neuroscience at Mayo Clinic in Florida.

If it is shown that, as suspected, these protein clumps are the cause of neuronal death and toxicity in these diseases, it may be possible to design therapies to break the clumps apart or to prevent the protein from accumulating in the first place, Dr. Petrucelli says.

Because the protein is found throughout the central nervous system in patients with ALS and frontotemporal dementia but not in other neurodegenerative diseases the researchers hope that in the future it can be tested through a spinal tap.

After Alzheimer's disease, frontotemporal dementia is the most common form of early onset neurodegenerative dementia. It is characterized by changes in personality, behavior and language due to loss of gray matter in the brain's frontal lobe. ALS destroys motor neuron cells that control essential muscle activity such as speaking, walking, breathing and swallowing.

This new discovery stems from a key finding, reported simultaneously in 2011 by Mayo researchers and scientists from the National Institutes of Health, that an unusual mutation a short DNA sequence repeated hundreds to thousands of times was found in almost 12 percent of familial frontotemporal dementia and more than 22 percent of familial ALS samples studied.


'/>"/>
Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Novel radiation therapy method shortens prostate cancer treatment time
2. Novel gene-searching software improves accuracy in disease studies
3. New Novel Looks at British NHS from the Inside
4. Fox Chase researchers discover novel role of the NEDD9 gene in early stages of breast cancer
5. IRSF awards $1.5 million for novel basic and translational research programs
6. Nobel laureate James Watson publishes novel hypothesis on curing late-stage cancers
7. PolyU Researchers Develop Novel Treatment for People with Hemiplegic Arms
8. 2 novel treatments for retinitis pigmentosa move closer to clinical trials
9. Neurological Wellness Center's Novel Neuro-Inflammation Inhibition Procedure that Induces Rapid Recovery from Alzheimer's, Stroke and Brain Injury is Now Being Taught in a Newly Released Video
10. Novel test identifies patients most likely to benefit from ALK inhibition therapy
11. Novel drug therapy targets aggressive form of non-Hodgkins lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... CT (PRWEB) , ... March 29, 2017 , ... HealthCareMandA.com ... —on Thursday, April 20, 2017, at 1:00 PM ET. A recording of the webinar ... the Interactive Webinar Series. , Home health and hospice companies are still popular targets ...
(Date:3/29/2017)... ... 2017 , ... Immunotherapy has emerged as one of the most promising options ... be the next revolution in our fight against this complex disease. One of the ... checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single analyte ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Pittsburgh now have easier access to the robotic-assisted total-hip and partial-knee replacement ... (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently started performing ...
(Date:3/29/2017)... PA (PRWEB) , ... March 29, 2017 , ... The ... W’80, WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift to ... deferred admission opportunity that will provide a pathway to a Wharton MBA for highly-qualified ...
(Date:3/29/2017)... ... ... has helped over 1.5 million SharePoint users learn the content management system faster and ... for SharePoint was at the farm level. Enterprises using SharePoint Online in Office 365 ... recently released a modified version of the Help System, VisualSP for Site Collections, which ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... -- According to a new market research report "Medical Radiation ... Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, Badges), Safety (Apron, Shields, Face ... market is expected to reach USD 1,215.4 Million by 2021 from USD ... 2021. Continue Reading ... ...
(Date:3/29/2017)... 29, 2017  The Pharmaceutical Care Management Association (PCMA) ... report on patient out-of-pocket spending: ... Services (CMS), the average amount spent out-of-pocket for drugs ... spending in 2016, down from 23% in 2006. ... not a coverage problem. Health plans don,t have unlimited ...
(Date:3/29/2017)... 29, 2017  Spiral Therapeutics, Inc. today announced ... Farma, S.L. for the worldwide exclusive rights to ... the field of otolaryngology for aggregate payments of ... The agreement provides Spiral with the option to ... product profile. Under the terms of the agreement, ...
Breaking Medicine Technology: